NASDAQ:PHIO Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free PHIO Stock Alerts $0.71 +0.03 (+4.44%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.66▼$0.7350-Day Range$0.64▼$1.0852-Week Range$0.50▼$6.85Volume217,368 shsAverage Volume369,264 shsMarket Capitalization$3.24 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Phio Pharmaceuticals alerts: Email Address Phio Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside466.6% Upside$4.00 Price TargetShort InterestHealthy0.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.42Based on 5 Articles This WeekInsider TradingAcquiring Shares$2,275 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPhio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePhio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.75% of the float of Phio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhio Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phio Pharmaceuticals has recently increased by 57.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHIO. Previous Next 0.9 News and Social Media Coverage News SentimentPhio Pharmaceuticals has a news sentiment score of -0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Phio Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PHIO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,275.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.77% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by Institutions57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Phio Pharmaceuticals Stock (NASDAQ:PHIO)Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More PHIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHIO Stock News HeadlinesApril 24, 2024 | investing.comPhio Pharmaceuticals reports progress on cancer therapy PH-762April 22, 2024 | benzinga.comWhy Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 22, 2024 | finance.yahoo.comIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsApril 22, 2024 | globenewswire.comIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsApril 16, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)April 11, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)April 3, 2024 | finance.yahoo.comNational Spotlight Features Phio’s Innovative RNAi Technology PlatformApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 3, 2024 | globenewswire.comNational Spotlight Features Phio's Innovative RNAi Technology PlatformApril 2, 2024 | globenewswire.comPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateMarch 21, 2024 | finance.yahoo.comPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesMarch 13, 2024 | globenewswire.comPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchMarch 10, 2024 | morningstar.comPhio Pharmaceuticals Corp PHIOMarch 6, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)March 6, 2024 | finance.yahoo.comPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersMarch 6, 2024 | globenewswire.comPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin DisordersFebruary 14, 2024 | uk.finance.yahoo.comDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030February 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)January 31, 2024 | finance.yahoo.comPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesDecember 19, 2023 | msn.comPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersDecember 7, 2023 | msn.comWhy Phio Pharmaceuticals Stock Is NosedivingDecember 7, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsNovember 10, 2023 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 10, 2023 | msn.comPhio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29November 9, 2023 | finance.yahoo.comPhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasSee More Headlines Receive PHIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHIO CUSIPN/A CIK1533040 Webphiopharma.com Phone(508) 767-3861Fax508-767-3862Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+466.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-134.66% Return on Assets-105.86% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio5.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book0.34Miscellaneous Outstanding Shares4,590,000Free Float4,557,000Market Cap$3.24 million OptionableNot Optionable Beta1.44 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Robert J. Bitterman (Age 73)President, CEO & Chairman Comp: $141.46kMs. Caitlin Kontulis (Age 38)VP of Finance & Administration and Secretary Ms. Linda M. MahoneySenior Vice President of DevelopmentKey CompetitorsAtrecaNASDAQ:BCELRevelation BiosciencesNASDAQ:REVBAridis PharmaceuticalsNASDAQ:ARDSAraviveNASDAQ:ARAVPhaseBio PharmaceuticalsNASDAQ:PHASView All CompetitorsInsidersRobert J BittermanBought 2,500 shares on 2/26/2024Total: $2,275.00 ($0.91/share)Robert J BittermanBought 1,000 shares on 6/30/2023Total: $2,880.00 ($2.88/share)Robert L FerraraBought 2,000 shares on 6/14/2023Total: $6,200.00 ($3.10/share)View All Insider Transactions PHIO Stock Analysis - Frequently Asked Questions Should I buy or sell Phio Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHIO shares. View PHIO analyst ratings or view top-rated stocks. What is Phio Pharmaceuticals' stock price target for 2024? 1 brokers have issued 12 month target prices for Phio Pharmaceuticals' stock. Their PHIO share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 466.6% from the stock's current price. View analysts price targets for PHIO or view top-rated stocks among Wall Street analysts. How have PHIO shares performed in 2024? Phio Pharmaceuticals' stock was trading at $0.76 at the start of the year. Since then, PHIO shares have decreased by 7.1% and is now trading at $0.7060. View the best growth stocks for 2024 here. Are investors shorting Phio Pharmaceuticals? Phio Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 33,800 shares, an increase of 57.9% from the March 31st total of 21,400 shares. Based on an average daily volume of 431,700 shares, the short-interest ratio is presently 0.1 days. Approximately 0.8% of the company's shares are short sold. View Phio Pharmaceuticals' Short Interest. When is Phio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PHIO earnings forecast. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp. (NASDAQ:PHIO) issued its quarterly earnings results on Monday, April, 1st. The company reported ($0.17) earnings per share (EPS) for the quarter. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST). How do I buy shares of Phio Pharmaceuticals? Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHIO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
